Hyloris Pharmaceuticals Management
Management criteria checks 2/4
Hyloris Pharmaceuticals' CEO is Stijn Van Rompay, appointed in Jan 2024, has a tenure of 1.08 years. total yearly compensation is €212.82K, comprised of 89.7% salary and 10.3% bonuses, including company stock and options. directly owns 36.67% of the company’s shares, worth €54.42M. The average tenure of the management team and the board of directors is 1.1 years and 5.1 years respectively.
Key information
Stijn Van Rompay
Chief executive officer
€212.8k
Total compensation
| CEO salary percentage | 89.7% |
| CEO tenure | 1.1yrs |
| CEO ownership | 36.7% |
| Management average tenure | 1.1yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€13m |
| Mar 31 2024 | n/a | n/a | -€14m |
| Dec 31 2023 | €213k | €191k | -€15m |
Compensation vs Market: Stijn's total compensation ($USD221.50K) is below average for companies of similar size in the German market ($USD832.51K).
Compensation vs Earnings: Insufficient data to compare Stijn's compensation with company performance.
CEO
Stijn Van Rompay (47 yo)
1.1yrs
Tenure
€212,820
Compensation
Mr. Stijn Van Rompay is a Co-Founder and Chief Executive Officer of Hyloris Pharmaceuticals SA and serves as its Director since 2020. He was the Chief Executive Officer of Alter Pharma, a high-growth pharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.1yrs | €212.82k | 36.67% € 54.4m | |
| Co-Founder | 1.1yrs | no data | 13.78% € 20.4m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 4.3yrs | no data | 0.12% € 172.3k | |
| Investor Relations Manager & Communications manager | no data | no data | no data |
1.1yrs
Average Tenure
47yo
Average Age
Experienced Management: 52U's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.1yrs | €212.82k | 36.67% € 54.4m | |
| Co-Founder | 5.1yrs | no data | 13.78% € 20.4m | |
| Chairman of the Board | 5.1yrs | €22.50k | no data | |
| Non-Executive Director | 5.1yrs | €12.50k | no data | |
| Independent Director | 5.1yrs | €22.50k | no data | |
| Independent Director | 1.1yrs | no data | no data | |
| Independent Director | 1.1yrs | no data | no data |
5.1yrs
Average Tenure
48yo
Average Age
Experienced Board: 52U's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 11:50 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hyloris Pharmaceuticals SA is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Allen | Berenberg |
| Laura Roba | Degroof Petercam |
| David Seynnaeve | Degroof Petercam |